Uddrag fra WSJ:
Novo Nordisk (NVO) has plans to slash the U.S. list prices of several insulin products by up to 75%, The Wall Street Journal reported Tuesday, following a similar move by the rival insulin maker Eli Lilly (LLY).
Danish drugmaker intends to cut the list price of its NovoLog insulin by 75% and the prices for Novolin and Levemir insulin products by 65% beginning Jan. 2024.
Plans are also afoot to cut prices of Novo’s (NVO) unbranded insulin products to match the revised prices of its corresponding brands.
“We have been working to develop a sustainable path forward that balances patient affordability, market dynamics and evolving policy changes,” Steve Albers, a Novo senior vice president, remarked.
“Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.”
With the changes, the list prices of Novo’s (NVO) NovoLog will stand at $139.71 and $72.34 for a five-pack of injection pens and a vial, respectively, compared to $558.83 and $289.36 earlier. The company said that the financial impact of the decision is uncertain.
Early this month, Lilly (LLY) said it would cut prices for Humalog and other insulins brands by 70%, effective Q4 2023. At the time, the Indianapolis, Indiana-based drugmaker also announced an expanded program to limit out-of-pocket costs for insulin to $35 or less for some consumers.
